Clinical characteristics of acute promyelocytic leukemia manifesting as early death
- Authors:
- Bai He
- Shaoyan Hu
- Guoqiang Qiu
- Weiying Gu
View Affiliations
Affiliations: Department of Hematology, The First People's Hospital of Changzhou (Third Affiliated Hospital of Suzhou University), Changzhou, Jiangsu 213003, P.R. China, Department of Hematology and Oncology, Children's Hospital of Suzhou University, Suzhou, Jiangsu 215003, P.R. China
- Published online on: July 23, 2013 https://doi.org/10.3892/mco.2013.155
-
Pages:
908-910
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Acute promyelocytic leukemia (APL) is currently considered to be a highly curable disease. However, early death (ED) remains a major cause of treatment failure in APL. The purpose of this study was to retrospectively review the morphological, immunophenotypic and molecular characteristics of 26 patients with APL resulting in ED. It was observed that elevated white blood cell (WBC) counts, lower fibrinogen concentrations, morphological variant M3v, CD34+ and the short form (S- or bcr3 form) of the PML‑RARα transcript were significantly associated with ED, mainly due to cerebral hemorrhage. Admission on weekends or holidays without immediate diagnosis or prompt administration of treatment for APL resulted in intracranial bleeding and was the major cause of ED. Therefore, it is recommended that APL and coagulopathy management treatments are promptly initiated only upon morphological and clinical suspicion of APL on admission, in order to reduce the risk of severe bleeding and lower the rate of ED.
View References
|
1
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adès L, Sanz MA, Chevret S, et al:
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a
comparison of French-Belgian-Swiss and PETHEMA results. Blood.
111:1078–1084. 2008.PubMed/NCBI
|
|
3
|
Lo-Coco F, Avvisati G, Vignetti M, et al:
Front-line treatment of acute promyelocytic leukemia with AIDA
induction followed by risk-adapted consolidation for adults younger
than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Blood. 116:3171–3179. 2010.
|
|
4
|
Yanada M, Matsushita T, Asou N, et al:
Severe hemorrhagic complications during remission induction therapy
for acute promyelocytic leukemia: incidence, risk factors, and
influence on outcome. Eur J Haematol. 78:213–219. 2007. View Article : Google Scholar
|
|
5
|
de la Serna J, Montesinos P, Vellenga E,
et al: Causes and prognostic factors of remission induction failure
in patients with acute promyelocytic leukemia treated with
all-trans retinoic acid and idarubicin. Blood. 111:3395–3402.
2008.
|
|
6
|
McClellan JS, Kohrt HE, Coutre S, Gotlib
JR, Majeti R, Alizadeh AA and Medeiros BC: Treatment advances have
not improved the early death rate in acute promyelocytic leukemia.
Haematologica. 97:133–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JH, Qiao B, Panageas KS, Schymura MJ,
Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM and Tallman
MS: Early death rate in acute promyelocytic leukemia remains high
despite all-trans retinoic acid. Blood. 118:1248–1254. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sanz MA, Grimwade D, Tallman MS, et al:
Management of acute promyelocytic leukemia: recommendations from an
expert panel on behalf of the European LeukemiaNet. Blood.
113:1875–1891. 2009. View Article : Google Scholar : PubMed/NCBI
|
